Seres Therapeutics, Inc. (MCRB) stock
MCRBNasdaqPharmaceutical PreparationsFiscal year ends December 31
$1.44+0.03 (+2.13%)
Close on Nov 18, 2026Market cap $14.32MP/E –Yield –
Seres Therapeutics revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Seres Therapeutics's revenue for the twelve months ending Jun 30, 2026 was $1.88M. For fiscal 2025 it was $789.00K. The highest annual figure on record is $144.93M in fiscal 2021.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $789.00K | – |
| FY2024 | Dec 31, 2024 | $0 | – |
| FY2023 | Dec 31, 2023 | $0 | -100.0% |
| FY2022 | Dec 31, 2022 | $7.13M | -95.1% |
| FY2021 | Dec 31, 2021 | $144.93M | +336.3% |
| FY2020 | Dec 31, 2020 | $33.22M | -3.7% |
| FY2019 | Dec 31, 2019 | $34.51M | +22.1% |
| FY2018 | Dec 31, 2018 | $28.27M | -11.9% |
| FY2017 | Dec 31, 2017 | $32.10M | +47.5% |
| FY2016 | Dec 31, 2016 | $21.77M | – |
| FY2015 | Dec 31, 2015 | $0 | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $736.00K | – |
| Q1 FY2026 | Mar 31, 2026 | $358.00K | – |
| Q4 FY2025 | Dec 31, 2025 | $438.00K | – |
| Q3 FY2025 | Sep 30, 2025 | $351.00K | – |
| Q2 FY2025 | Jun 30, 2025 | $0 | – |
| Q1 FY2025 | Mar 31, 2025 | $0 | – |
| Q4 FY2024 | Dec 31, 2024 | $0 | -100.0% |
| Q3 FY2024 | Sep 30, 2024 | $0 | -100.0% |
| Q2 FY2024 | Jun 30, 2024 | $0 | -100.0% |
| Q1 FY2024 | Mar 31, 2024 | $0 | – |
| Q4 FY2023 | Dec 31, 2023 | $64.00K | -93.4% |
| Q3 FY2023 | Sep 30, 2023 | $310.00K | -91.0% |
| Q2 FY2023 | Jun 30, 2023 | $126.47M | +10300.7% |
| Q1 FY2023 | Mar 31, 2023 | -$522.00K | -135.0% |
| Q4 FY2022 | Dec 31, 2022 | $975.00K | -86.5% |
| Q3 FY2022 | Sep 30, 2022 | $3.44M | -97.3% |
| Q2 FY2022 | Jun 30, 2022 | $1.22M | -76.9% |
| Q1 FY2022 | Mar 31, 2022 | $1.49M | -73.9% |
| Q4 FY2021 | Dec 31, 2021 | $7.22M | -58.9% |
| Q3 FY2021 | Sep 30, 2021 | $126.73M | +8843.2% |
| Q2 FY2021 | Jun 30, 2021 | $5.26M | -12.9% |
| Q1 FY2021 | Mar 31, 2021 | $5.72M | -30.2% |
| Q4 FY2020 | Dec 31, 2020 | $17.56M | +130.4% |
| Q3 FY2020 | Sep 30, 2020 | $1.42M | -79.8% |
| Q2 FY2020 | Jun 30, 2020 | $6.05M | -51.8% |
| Q1 FY2020 | Mar 31, 2020 | $8.19M | +11.9% |
| Q4 FY2019 | Dec 31, 2019 | $7.62M | -28.3% |
| Q3 FY2019 | Sep 30, 2019 | $7.03M | -22.4% |
| Q2 FY2019 | Jun 30, 2019 | $12.53M | +171.7% |
| Q1 FY2019 | Mar 31, 2019 | $7.32M | +84.4% |
| Q4 FY2018 | Dec 31, 2018 | $10.63M | +247.8% |
| Q3 FY2018 | Sep 30, 2018 | $9.06M | -60.7% |
| Q2 FY2018 | Jun 30, 2018 | $4.61M | +53.0% |
| Q1 FY2018 | Mar 31, 2018 | $3.97M | +31.7% |
| Q4 FY2017 | Dec 31, 2017 | $3.06M | +0.7% |
| Q3 FY2017 | Sep 30, 2017 | $23.02M | +76.8% |
| Q2 FY2017 | Jun 30, 2017 | $3.01M | – |
| Q1 FY2017 | Mar 31, 2017 | $3.02M | – |
| Q4 FY2016 | Dec 31, 2016 | $3.04M | – |
| Q3 FY2016 | Sep 30, 2016 | $13.02M | – |
See a number that looks wrong?